Clinical study of Tongren Wuji Baifeng Pill in the treatment of hyperuricemia in patients with chronic kidney disease

A prospective, multicenter, randomized, open parallel controlled clinical trial of Tongren Wuji Baifeng Pill in the treatment of hyperuricemia in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005691

Enrollment

Unknown

Registered

2022-03-10

Start date

2022-04-01

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease with hyperuricemia

Interventions

research group:General lifestyle intervention + basic treatment + Tongren Wuji Baifeng Pill 1 pill, 2 times a day, taken with warm water, intervention for 3 months

control group:General lifestyle intervention + basic treatment, intervention for 3 months

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) Age 18-70 years old, regardless of gender (2) Patients meeting the diagnostic criteria for CKD and staged as CKD stage 2-4 (15 ml/min.1.73m2=GFR<90 ml/min.1.73m2) (3) Meeting the diagnostic criteria of hyperuricemia (4) Patients with evidence of spleen and kidney deficiency and blood deficiency with stasis (5) Signed informed consent form

Exclusion criteria

Exclusion criteria: (1) Taking one or more of the Western medicine uric acid-lowering drugs, such as allopurinol, benzbromarone, probenecid, febuxostat, etc. within the last 1 month (2) Uncontrollable hypertension/hypotension: systolic blood pressure = 200 mmHg or diastolic blood pressure = 110 mmHg; or systolic blood pressure = 90 mmHg or diastolic blood pressure = 60 mmHg (3) Change in blood creatinine level of more than 50% in the last 3 months (4) Combination of various acute infections, or with severe infections, severe anaemia, etc. (5) History or complications of malignancy (6) Organic heart disease, such as congenital heart disease, rheumatic heart disease, etc. (7) Severe liver function abnormalities (ALT or AST greater than 3 times the upper limit of normal) (8) Pregnant or lactating women (9) Participating in any other clinical trial (10) Any other reason why the investigator considers it inappropriate to participate in this study

Design outcomes

Primary

Measure	Time frame
Serum uric acid;	—

Secondary

Measure	Time frame
Fasting blood glucose;Urinary Albumin Creatinine Ratio;Low-density lipoprotein;Triglycerides;Urine routine;Serum Cystatin C;Serum albumin;Cholesterol;Chinese Medicine Evidence Score;Estimation of glomerular filtration rate;Serum creatinine;	—

Countries

China

Contacts

Public ContactRao xiangrong

raoyisheng@163.com010-88001057

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026